BCL9 and neoplasm: In agreement with the previous research finding, BCL9 depletion was reported to benefit CD8+ T cells infiltration into CRC tumor and improve anti-PD-1 immunotherapy response in murine models via increased VAV1 phosphorylation in CD8+ T cells and enhanced GLI1 and PATCH expression, promoting CD155 production in CRC cells.